Drug Database
IN

insulin

✓ Approved

MJ Biotech · INSR · Recombinant Proteins

What is insulin?

insulin is a recombinant proteins developed by MJ Biotech. It is approved for therapeutic indications via injectable (others).

Drug Profile

CompanyMJ Biotech
Drug ClassRecombinant Proteins
Molecular TargetINSR
RouteInjectable (Others)
StatusApproved

Mechanism of Action

Molecular Targets

insulin acts on 1 molecular target:

INSRinsulin receptor (CD220, HHF5)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

insulin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
InvestigationsGlucose tolerance test abnormal✓ Approved

Related Research Articles

PubMedMolecular metabolism2026-07-17

Muscle in Fat Trouble: The Rise of IMAT in Metabolic and Musculoskeletal Disease.

Weik Vanessa V, Birkenfeld Andreas L AL, Peter Andreas A, Weigert Cora C et al.

Intermuscular adipose tissue (IMAT) is increasingly recognized as a contributor to insulin resistance and metabolic dysfunction in type 2 diabetes (T2D). Accumulation of IMAT was found to correlate with impaired skeletal muscle insulin sensitivity, as well as a generally reduced muscle strength and physical performance in humans. Beyond serving as an energy depot at physiological levels, increased IMAT is thought to actively impair muscle metabolism through secretion of adipokines, cytokines and lipid intermediates that create an inflammatory environment and modulate insulin signaling pathways. This review discusses current evidence on the pathophysiological role of IMAT based on clinical studies, including interventions, and current mechanistic insight from biopsied human IMAT. We further explore traditional and emerging methods to investigate IMAT that could expand mechanistic understanding of IMAT-muscle-crosstalk, highlighting their strengths and limitations. Human in vitro co-culture-models are valuable future tools for dissecting cellular and molecular responses. Despite growing interest in IMAT as a potential key player in metabolic disease, uncertainty remains about its origin, regulation and functionality. We suggest further research to integrate and intertwine traditional imaging techniques, multi-omics characterization of IMAT biopsies and advanced, physiologically relevant human in vitro systems to close these knowledge gaps to develop therapeutic strategies targeting metabolic disease.

PubMedClinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery2026-07-17

Adjustable Vocal Implant System (VOIS) for Unilateral Vocal Fold Paralysis: Short-Term Outcomes From a 12-Patient Case Series.

Kebbe Sam S, Keane Michael M, Gao Chuanyu C, Devabalan Yadsan Y et al.

Unilateral vocal cord palsy (UVCP) significantly affects phonation and swallowing. While injection laryngoplasty and medialisation thyroplasty are effective, both may require revision. Vocal Implant System (VOIS; APrevent Biotech GmbH) is an adjustable titanium-silicone thyroplasty implant that allows postoperative modification, potentially reducing the need for further surgery. Twelve patients, seven male and five female, underwent VOIS implantation. Voice outcomes were assessed pre- and postoperatively using the GRBAS scale and the Voice Handicap Index-10 (VHI-10). The composite GRBAS score improved significantly from 9.0 ± 1.87 to 3.75 ± 2.49 (p = 0.0024). The VHI-10 decreased from 25.75 ± 9.36 to 14.92 ± 9.55 (p = 0.0093). No intra- or postoperative complications occurred. Two patients required postoperative implant volume adjustments-one performed in clinic and one under local anaesthetic in theatre. The VOIS implant thyroplasty demonstrated significant improvement in both perceptual and patient-reported voice outcomes with a favourable safety profile. Larger, long-term studies are warranted to confirm its comparative efficacy and durability.

PubMedAnnals of medicine2026-07-17

Recombinant human collagen XVII protects epidermal stem cells from blue light-induced photoaging by downregulating the Notch pathway.

Wang Xudong X, Li Qiang Q, Yang Xin X, Bai Yu Y et al.

Epidermal stem cell (ESC) degeneration is closely associated with skin aging and functional deterioration. Type XVII collagen (COL17A1) critically regulates ESC polarity and epidermal homeostasis. This study investigated the protective effects of recombinant human COLXVII (rhCol17) against blue light-induced photoaging, particularly on ESC. Blue light-induced photoaging models were established using in vitro ESCs and in vivo Sprague-Dawley rats. Transcriptomic profiling was conducted to systematically elucidate the underlying mechanisms. In photoaging ESCs, rhCol17 enhanced ESC viability and migratory capacity, decreased senescence cells, while suppressing ROS production and the secretion of pro-inflammatory factors interleukin (IL)-6, IL-1β and tumor necrosis factor-α. Furthermore, rhCol17 upregulated stem cell markers COL17A1, ITGB1, ITGA6 and P63. In photoaging rat models, rhCol17 alleviated skin dryness, reduced epidermal thickness, delayed aging, and increased the levels of COL17A1 and ITGB1. Importantly, rhCol17 treatment does not affect organ histology or biochemical parameters in rats. Mechanistically, rhCol17 could inhibit the levels of Notch1 and HES1, and senescence markers P16, P21, and P53 in photoaging ESCs and rat skin. Additionally, the ADAM10 inhibitor GI254023X slightly reduced or did not significantly alter the proportion of senescent cells or the expression levels of P16, P21, and P53 in rhCol17-treated BL-induced ESCs, whereas the Notch activator VPA significantly reversed these protective effects of rhCol17. This study demonstrates that rhCol17 counteracts blue light-induced ESC dysfunction and epidermal photoaging, suggesting therapeutic potential for photoaging intervention.

PubMedInternational journal of cancer2026-07-17

Survival Outcomes Associated With Short-Acting Versus Long-Acting G-CSF Use During First-Line Chemoimmunotherapy for Advanced Lung Cancer: A Retrospective Study.

Xiong Yanjuan Y, Guo Wenjing W, Ma Chenxi C, Ren Xiubao X et al.

While granulocyte colony-stimulating factor (G-CSF) is used to prevent and treat chemotherapy-induced neutropenia, it also regulates key immune cells and may therefore affect the efficacy of immunotherapy. Short-acting and long-acting G-CSF have similar efficacy in managing neutropenia, but they differ in effects on immune cells. However, the overall impact of G-CSF and its different formulations on survival in advanced lung cancer patients receiving chemoimmunotherapy remains unclear. This retrospective study enrolled patients with advanced primary lung cancer receiving first-line chemoimmunotherapy at Tianjin Medical University Cancer Institute and Hospital. The primary outcome was overall survival (OS). Inverse probability of treatment weighting (IPTW) was used to balance heterogeneity between groups. Kaplan Meier and Cox models were used to estimate OS and progression-free survival (PFS). Among 606 patients, 308 developed neutropenia and received G-CSF support (pegylated recombinant human G-CSF [PEG-rhG-CSF]: 183; recombinant human G-CSF [rhG-CSF]: 125); 298 without neutropenia received no G-CSF. After IPTW, no significant differences in PFS and OS were observed between G-CSF group and non-G-CSF group. Patients receiving rhG-CSF had significantly improved OS (42.6 vs. 28.2 months, p = 0.041) and PFS (15.4 vs. 9.4 months, p < 0.001) than those receiving PEG-rhG-CSF. Multivariable analysis confirmed rhG-CSF as a favorable independent prognostic factor for both PFS and OS. Among patients with advanced primary lung cancer receiving first-line chemoimmunotherapy, G-CSF support effectively abrogates the adverse survival impact of chemotherapy-induced neutropenia. Moreover, rhG-CSF was associated with improved clinical outcomes versus PEG-rhG-CSF. Prospective randomized trials are required to validate these findings and guide clinical practice.

PubMedMicrobial cell factories2026-07-17

Enhancing recombinant eGFP secretion in P. tricornutum by optimizing culture conditions.

Gargouch Nesrine N, Charrier Aurélie A, Toustou Charlotte C, Bougaran Gaël G et al.

Phaeodactylum tricornutum is a promising candidate for the production of recombinant therapeutic proteins including antibodies. So far, low secretion yields remain a significant bottleneck for pharmaceutical applications. Towards the objective to increase production yield of secreted recombinant protein, this study investigates the optimization of environmental and nutritional parameters, under laboratory conditions, to maximize the production of a model secreted recombinant protein (eGFPsec) under the control of the Nitrate Reductase promoter (PNR). We evaluated the interplay between nitrate availability, Photosynthetic Photon Flux Density (PPFD), and pH level within both natural and artificial seawater matrices. Our results demonstrate that while PNR activity does not increase with nitrate concentrations beyond non-limiting levels, a PPFD of 150 µmol photons m- 2 s- 1 significantly enhances eGFPsec accumulation in the medium. Interestingly, cultures grown in Natural Sea Water under pH-regulated conditions (pH = 8) exhibited markedly higher secreted-eGFP fluorescence compared to those in artificial seawater. These findings highlight the importance of optimizing key environmental and nutritional parameters to improve secretion recombinant protein yields. By identifying key drivers of eGFP fluorescence-based productivity and accumulation in the medium, this work provides actionable insights for process optimization, reinforcing the potential of P. tricornutum as a robust and cost-effective platform for industrial microalgae-based biomanufacturing.

PubMedDiabetes technology & therapeutics2026-07-17

Evaluation of an Objective Measure of Mealtime Insulin Administration Frequency in Emerging Adults with Type 1 Diabetes.

Pierce Jessica S JS, Clements Mark A MA, Lockee Brent B, Patton Susana R SR

Objective measures of self-management are critical for understanding glycemic outcomes in individuals with type 1 diabetes (T1D). The mealtime insulin bolus score (BOLUS), derived from insulin pump data, is a validated indicator of mealtime insulin engagement in pediatric T1D populations, but its validity in emerging adults (EA) is unknown. We examined associations between BOLUS scores and glycemic outcomes (HbA1c and continuous glucose monitoring metrics) in 347 EA with T1D (ages 18-22). Higher BOLUS scores were associated with lower HbA1c (r = -0.24, P < 0.001), greater time in range (r = 0.23, P < 0.001), and lower time above range (r = -0.23, P < 0.001). The mean BOLUS score (1.17) was substantially lower than the previously reported mean pediatric BOLUS score. Findings support the validity of BOLUS as an objective behavioral measure in EA with T1D and highlight reduced mealtime insulin engagement during this developmental period.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about insulin